Citadel Advisors’s Basel Medical BMGL Stock Holding History

Citadel Advisors’s Portfolio BMGL Stock Details BMGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,056	Closed	-$12.1K	–	14653
2025 Q4	$12.1K	Sell	2,056 -5,694	-73%	-$84.1K	﹤0.01%	12418
2025 Q3	$169K	Buy	+7,750	New	+$194K	﹤0.01%	11432

Other funds holding BMGL

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

T3 Companies New York $93.7M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's BMGL Position: Q1 2026 in Review

Citadel Advisors sold out of Basel Medical (BMGL) in Q1 2026, closing a stake of 2,056 shares — an estimated $12.1K sold.

Citadel Advisors first reported a position in BMGL in Q3 2025 and held it in 2 quarters. The position peaked at $169K in Q3 2025. 4 funds tracked by Wall St. Rank hold BMGL as of Q1 2026.

Citadel Advisors reported no remaining Basel Medical position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 2,056 Basel Medical shares in Q1 2026, an estimated $12.1K.
Citadel Advisors first reported a position in Basel Medical in Q3 2025 and held it in 2 quarters.
Citadel Advisors's Basel Medical position peaked at $169K in Q3 2025.
4 funds tracked by Wall St. Rank held Basel Medical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.